Abstract:Toxoplasma gondii is an intracellular protozoan parasite that infects all nucleated cells except the red blood cells. Currently, nucleic acid vaccines are being widely investigated in Toxoplasma gondii control, and several nucleic acid vaccine candidate antigens have shown good protection in various studies. The aim of this study was to construct a nucleic acid vaccine with Toxoplasma gondii SRS29C as the target gene. We explored the nucleic acid vaccine with Toxoplasma surface protein SRS29C and the combined gene of SRS29C and SAG1 and evaluated its immunoprotective effect against Toxoplasma gondii. To amplify the gene fragment and clone it to the expression vector, the recombinant plasmid pEGFP-SRS29C was constructed by PCR. Eukaryotic cells were transfected with the plasmid, and the expression of the target protein was assessed using the Western blot method. The level of serum IgG was determined via ELISA, and the splenic lymphocyte proliferation ability was detected using the CCK-8 method. The percentages of CD4+ and CD8+ T cells were measured by flow cytometry. Mice were immunised three times with single-gene nucleic acid vaccine and combination vaccine. Splenic lymphocytokine expression was determined using ELISA kits. The mice's survival time was monitored and recorded during an in vivo insect assault experiment, and the vaccine's protective power was assessed. The outcomes showed that PCR-amplification of an SRS29C gene fragment was successful. The 4,733-bp vector fragment and the 1,119-bp target segment were both recognised by double digestion. Additionally, after transfection of the recombinant plasmid pEGFP-SRS29C, Western blot examination of the extracted protein revealed the presence of a target protein strip at 66 kDa. The test results demonstrated that the IgG content in the serum of the pEGFP-SRS29C group and the co-immunization group was significantly higher than that of the PBS group and the empty vector group. The IgG potency induced by the co-immunization group was higher than that of the pEGFP-SRS29C group and the pEGFP-SAG1 group, the number of splenic lymphocyte proliferation number was higher than that of the PBS group and the empty vector group. The CD4+/CD8+ T ratio was higher than that of the PBS group and the empty vector group. The expression of IFN-γ and TNF-α in the splenocytes of the pEGFP-SRS29C group and the combined immunisation group was significantly higher following antigen stimulation. In the worm attack experiments, mice in the PBS and empty vector groups perished within 9 days of the worm attack, whereas mice in the pEGFP-SRS29C group survived for 18 days, mice in the pEGFP-SAG1 group survived for 21 days, and mice in the co-immunization group survived for 24 days. This demonstrates that the constructed Toxoplasma gondii nucleic acid vaccine pEGFP-SRS29C and the combined gene vaccine can induce mice to develop certain humoral and cellular immune responses, and enhance their ability to resist Toxoplasma gondii infection.

Recombinant Expression of Cell Penetrating Peptide TAT Fused with Three Antigens of Toxoplasma Gondii

Prokaryotic cell expression of the surface antigen 1 gene from GJS strain of Toxoplasma gondii and its antigenicity analysis

Construction of Toxoplasma gondii SRS29C nucleic acid vaccine and comparative immunoprotective study of an SRS29C and SAG1 combination

Evaluation of Protective Effect of Multiantigenic DNA Vaccine Encoding MIC3 and ROP18 Antigen Segments of Toxoplasma Gondii in Mice.

EXPRESSION OF TOXOPLASMA GONDII MULTI-ANTIGENIC GENE ENCODING SAG1 AND ROP1 IN ECOLI

Immunoprotection by a Nucleic Acid Vaccine from the GRA1 Gene of Toxoplasma Gondii

Construction of Eukaryotic Expression Recombinant Plasmid Containing Toxoplasma Gondii GRA2 and Expression in Vitro

Toxoplasma Gondii: Bioinformatics Analysis, Cloning and Expression of a Novel Protein TgIMP1

A recombinant protein vaccine encoding Toxoplasma gondii Cyst wall 2 (dense granule protein 47) provides partial protection against acute and chronic T. gondii infection in BALB/c mice

The construction and characterization of multiple-epitopes vaccine of two new genes of Toxoplasma gondii

Construction and Identification of Recombinant Plasmid Containing SAG1 and MIC3 from Toxoplasma Gondii

Toxoplasma gondii cathepsin proteases are undeveloped prominent vaccine antigens against toxoplasmosis

EXPRESSION AND PURIFICATION OF SOLUBLE FUSION PROTEIN OF TOXOPLASMA GONDII SAG1 IN ESCHERICHIA COLI

Toxoplasma Gondii: Expression and Characterization of a Recombinant Protein Containing SAG1 and GRA2 in Pichia Pastoris

Toxoplasma Gondii: Vaccination with a DNA Vaccine Encoding T- and B-cell Epitopes of SAG1, GRA2, GRA7 and ROP16 Elicits Protection Against Acute Toxoplasmosis in Mice

Immunological Screening of Toxoplasma Tachyzoite Cdna Expression Libraries with Serum from Infected Rats

Protective effect against toxoplasmosis in BALB/C mice vaccinated with recombinant Toxoplasma gondii CDPK3, GRA35, and ROP46 protein cocktail vaccine

Cloning and Prokaryotic Expression of Toxoplasma Gondii SAGⅠGene

Evaluation of protective immune responses induced by DNA vaccines encoding Toxoplasma gondii surface antigen 1 (SAG1) and 14-3-3 protein in BALB/c mice

In vitro amplification,cloning of the GRA4 gene of Toxoplasma gondii and its expression in Mycobacterium smegmatis mc~2 155

AMPLIFICATION, CLONING AND PROKARYOTIC EXPRESSION OF GENE FOR MAJOR SURFACE ANTIGEN OF TOXOPLASMA GONDII